Inactivated Vaccines

Global Inactivated Vaccines Market to Reach US$54.1 Billion by 2030

The global market for Inactivated Vaccines estimated at US$41.6 Billion in the year 2024, is expected to reach US$54.1 Billion by 2030, growing at a CAGR of 4.5% over the analysis period 2024-2030. Viral Vaccine, one of the segments analyzed in the report, is expected to record a 5.3% CAGR and reach US$35.3 Billion by the end of the analysis period. Growth in the Bacterial Vaccine segment is estimated at 3.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.3 Billion While China is Forecast to Grow at 8.3% CAGR

The Inactivated Vaccines market in the U.S. is estimated at US$11.3 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$11.3 Billion by the year 2030 trailing a CAGR of 8.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.8% and 3.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.6% CAGR.

Global Inactivated Vaccines Market – Key Trends & Drivers Summarized

How Do Inactivated Vaccines Maintain Their Relevance in a Rapidly Evolving Immunization Landscape?
Inactivated vaccines, which contain pathogens that have been killed through chemical or physical processes, continue to serve as a cornerstone of global immunization efforts due to their robust safety profile and broad applicability. Unlike live-attenuated vaccines, inactivated formulations pose no risk of reversion to virulence, making them especially critical for immunocompromised individuals, the elderly, and pregnant women. These vaccines are widely used for diseases such as hepatitis A, rabies, polio (IPV), Japanese encephalitis, and influenza, with emerging relevance in pandemic preparedness scenarios.

Their non-replicating nature means booster doses are often required, yet this trade-off is balanced by their ability to induce strong humoral immune responses with well-understood safety parameters. Governments and global health agencies continue to prioritize inactivated vaccines in their procurement strategies, particularly in regions where cold chain stability, regulatory acceptance, and public trust in vaccine safety are high priorities. Moreover, the role of inactivated vaccines in combination formulations—particularly in pediatric immunization schedules—is reinforcing their relevance across global markets.

What Technological Innovations Are Reshaping the Development and Delivery of Inactivated Vaccines?
A wave of innovation is enhancing the scalability, purity, and immunogenicity of inactivated vaccine platforms. Cell culture-based production methods, such as Vero and MDCK cell lines, are replacing traditional egg-based and animal-derived substrates, resulting in safer and more consistent manufacturing. These platforms are particularly useful for producing vaccines against polio, influenza, and rabies. Moreover, novel adjuvants like aluminum salts, MF59, and AS03 are being incorporated to amplify immune responses and reduce the number of required doses.

Another critical advancement is the development of thermostable and lyophilized formulations, which are designed to maintain potency in high-temperature or low-resource settings. This is especially important in rural regions of Africa and Southeast Asia where cold chain logistics are difficult to maintain. In addition, digital tracking systems and smart packaging technologies are being integrated to ensure proper storage, traceability, and usage compliance. These improvements are not only optimizing vaccine logistics but also supporting global mass immunization campaigns, particularly during emergencies like pandemics or sudden disease outbreaks.

Which Disease Targets and Geographies Are Fueling Demand for Inactivated Vaccines?
Demand for inactivated vaccines is particularly strong in pediatric immunization programs and in infectious disease control initiatives across Asia-Pacific, Latin America, and parts of Africa. IPV is increasingly replacing oral polio vaccines as countries move into the final stages of polio eradication, while inactivated rabies vaccines are crucial in managing post-exposure prophylaxis in endemic countries. Seasonal influenza vaccination, which often relies on inactivated quadrivalent formulations, remains a major growth segment in North America and Europe, especially in aging populations and those with chronic diseases.

Emerging infectious threats such as COVID-19 have also reignited global interest in inactivated vaccine platforms. Several COVID-19 vaccines developed using traditional inactivation methods have been deployed at scale in countries like China, India, and the UAE, showcasing the speed and scalability of this platform in crisis response. Additionally, zoonotic threats such as avian influenza and tick-borne encephalitis are further driving the development and deployment of inactivated vaccines for both human and veterinary applications. Public-private partnerships are supporting local manufacturing in lower-income nations, ensuring more equitable access to these vaccines across geographic and economic divides.

The Growth in the Inactivated Vaccines Market Is Driven by Several Factors…
It is driven by the increasing global focus on vaccine safety, particularly for use in vulnerable populations and immunocompromised individuals. Technological advancements in cell culture production and adjuvant development are improving the efficiency, potency, and scalability of inactivated vaccines, making them more suitable for both routine and emergency immunization campaigns. The rising prevalence of zoonotic diseases and emerging pandemics is also accelerating demand for flexible and rapid-response vaccine platforms, in which inactivated vaccines have proven critical.

Additionally, policy shifts such as the transition from OPV to IPV in polio-endemic and transitioning countries are expanding the adoption base of inactivated formulations. Government-supported programs in rabies control, hepatitis A prevention, and pandemic influenza preparedness are further bolstering market growth, supported by Gavi, WHO, and regional health alliances. Increasing uptake of combination pediatric vaccines, including IPV and other inactivated components, is streamlining immunization schedules and improving compliance. The expansion of vaccine manufacturing infrastructure in developing regions, supported by technology transfer and international funding, is helping to reduce production costs and improve global supply security—further fueling the sustained growth of the inactivated vaccines market.

SCOPE OF STUDY:

The report analyzes the Inactivated Vaccines market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Vaccine Type (Viral Vaccine Type, Bacterial Vaccine Type); Inactivation Method (Solvent Detergent Method, Radiation Method, pH Concentration, Other Inactivation Methods); Administration Route (Oral, Subcutaneous, Intravenous); End-User (Hospitals End-User, Specialty Clinics End-User, Homecare Settings End-User, Other End-Users)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 36 Featured) -

• Astellas Pharma Inc.
• Bavarian Nordic A/S
• Bharat Biotech International Ltd.
• Biological E Limited
• Boehringer Ingelheim International GmbH
• CanSino Biologics Inc.
• CSL Limited
• Daiichi Sankyo Company, Limited
• Emergent BioSolutions Inc.
• GlaxoSmithKline plc
• Hualan Biological Engineering Inc.
• Inovio Pharmaceuticals, Inc.
• Johnson & Johnson Services Inc.
• Merck & Co., Inc.
• Mitsubishi Tanabe Pharma Corporation
• Novartis AG
• Novavax, Inc.
• Pfizer Inc.
• Sanofi Pasteur
• Serum Institute of India Pvt. Ltd.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.